Table 4 Top 10 significant gene-wide methylation sites for each measure
Sleep Measure | Chr | Position | Gene | Î’1 | (SE) | Q value | Function/disease in previous studies2 | Location |
|---|---|---|---|---|---|---|---|---|
Bedtime (hh:mm) | ||||||||
PSG | chr2 | 113,240,584 | TTL | 3.8 | 0.5 | 9.4E-08 | Neoplasms | Intragenic |
chr5 | 92,956,911 | FAM172A | 2.5 | 0.3 | 9.4E-08 | Major Depressive Disorder | Intragenic | |
chr9 | 132,258,570 | LINC00963 | 1.1 | 0.1 | 2.6E-07 | Body Height | Intragenic | |
chr2 | 27,434,990 | SLC5A6 | 15.4 | 2.1 | 3.4E-07 | Metabolic Homeostasis | Intragenic | |
chr21 | 37,432,401 | SETD4 | 2.3 | 0.3 | 3.4E-07 | Neoplasms | Intragenic | |
chr11 | 46,722,403 | ZNF408 | 0.8 | 0.1 | 4.6E-07 | Exudative vitreoretinopathy | Intragenic | |
chr22 | 24,237,682 | MIF-AS1 | 10.8 | 1.5 | 4.6E-07 | Autoimmune Disorders | Intragenic | |
chr15 | 68,569,779 | FEM1B | 1.4 | 0.2 | 4.6E-07 | Diabetes Mellitus | Upstream | |
chr3 | 196,014,497 | PCYT1A | 1.0 | 0.1 | 4.6E-07 | Spondylometaphyseal Dysplasia | Intragenic | |
chr11 | 64,084,832 | TRMT112 | 5.9 | 0.8 | 4.6E-07 | Eosinophil count | Intragenic | |
Sleep latency (min) | ||||||||
Self-report | chr10 | 135,044,054 | UTF1 |  − 118 | 15.0 | 1.6E-07 | Neoplasms | Intragenic |
chr2 | 209,131,065 | PIKFYVE |  − 2512 | 335.0 | 2.2E-07 | Fleck corneal dystrophy | Intragenic | |
chr14 | 101,034,180 | BEGAIN |  − 113 | 15.1 | 2.2E-07 | Synapse structural protein, platelet count | Intragenic | |
chr11 | 101,918,111 | CFAP300 |  − 120 | 16.4 | 3.2E-07 | Ciliary Dyskinesia | Upstream | |
chr20 | 52,000,535 | TSHZ2 | 108 | 14.9 | 3.2E-07 | Waist-Hip Ratio, Blood Pressure | Intragenic | |
chr19 | 5,139,393 | KDM4B |  − 120 | 16.4 | 3.2E-07 | Medulloblastoma | Intragenic | |
chr3 | 46,008,935 | FYCO1 | 110 | 15.3 | 5.4E-07 | Cataracts | Intragenic | |
chr2 | 74,719,532 | TTC31 | 113 | 15.8 | 5.4E-07 | ADHD, substance abuse | Intragenic | |
chr16 | 29,918,111 | SMG1P2 | 100 | 13.8 | 5.4E-07 | pseudogene | Intragenic | |
chr4 | 1,195,805 | SPON2 |  − 101 | 14.3 | 7.2E-07 | Neoplasms | Intragenic | |
ACT | chr2 | 178,937,545 | PDE11A |  − 244 | 37.4 | 1.2E-04 | Adrenocortical Disease, Depression | Intragenic |
chr1 | 3,688,710 | CCDC27 |  − 758 | 116.8 | 1.2E-04 | Hemoglobin Level | Downstream | |
chr2 | 200,820,452 | TYW5 |  − 424 | 65.8 | 1.2E-04 | Mathematical ability | Intragenic | |
chr3 | 14,988,783 | FGD5-AS1 |  − 445 | 69.0 | 1.2E-04 | Systolic Blood Pressure | Intragenic | |
chr12 | 862,461 | WNK1 |  − 516 | 81.2 | 1.4E-04 | Neuropathy, Hypertension | Intragenic | |
chr11 | 66,026,044 | KLC2 |  − 430 | 67.7 | 1.4E-04 | Spastic paraplegia, optic atrophy, and neuropathy | Intragenic | |
chr18 | 29,523,469 | TRAPPC8 |  − 705 | 114.4 | 1.5E-04 | Neoplasms | Downstream | |
chr19 | 54,693,401 | MBOAT7 |  − 501 | 81.1 | 1.5E-04 | Intellectual disability | Intragenic | |
chr1 | 1,342,991 | MRPL20 |  − 665 | 106.9 | 1.5E-04 | Body Height | Downstream | |
chr8 | 11,660,746 | FDFT1 |  − 468 | 76.2 | 1.5E-04 | Intellectual Disability, Substance Abuse | Intragenic | |
PSG | chr12 | 96,429,291 | LTA4H |  − 1085 | 154.1 | 9.3E-06 | Atherosclerosis, Depressive Disorder | Intragenic |
chr13 | 22,032,682 | ZDHHC20 |  − 1134 | 162.2 | 9.3E-06 | Neoplasms | Intragenic | |
chr7 | 75,623,771 | TMEM120A |  − 468 | 71.3 | 5.4E-05 | Coffee consumption | Intragenic | |
chr13 | 53,024,718 | VPS36 |  − 1001 | 154.6 | 5.4E-05 | Decompression Sickness, Neoplasms | Intragenic | |
chr13 | 111,806,083 | ARHGEF7 |  − 1221 | 195.0 | 1.1E-04 | Psychotic Disorders, Neoplasms | Intragenic | |
chr5 | 70,883,001 | MCCC2 |  − 1687 | 277.7 | 1.8E-04 | 3-methylcrotonyl-CoA carboxylase 2 deficiency | Upstream | |
chr17 | 77,770,886 | CBX8 |  − 2254 | 376.9 | 1.8E-04 | Breast Carcinoma | Intragenic | |
chr6 | 150,185,629 | RAET1E-AS1 |  − 1565 | 259.2 | 1.8E-04 | Unknown | Intragenic | |
chr1 | 228,871,178 | RHOU |  − 359 | 59.7 | 1.8E-04 | Neoplasms | Intragenic | |
chr5 | 177,631,277 | HNRNPAB |  − 1184 | 198.3 | 1.8E-04 | Neoplasms | Upstream | |
Sleep onset (hh:mm) | ||||||||
Self-report | chr3 | 195,447,691 | MUC20 | 5 | 0.8 | 3.7E-02 | Neoplasms | Upstream |
PSG | chr7 | 75,623,771 | TMEM120A |  − 8 | 1.4 | 5.8E-03 | Coffee consumption | Intragenic |
chr12 | 96,429,291 | LTA4H |  − 19 | 3.3 | 6.0E-03 | Atherosclerosis, Depressive Disorder | Intragenic | |
chr13 | 22,032,682 | ZDHHC20 |  − 19 | 3.4 | 6.0E-03 | Neoplasms | Intragenic | |
chr12 | 72,057,164 | ZFC3H1 |  − 8 | 1.5 | 6.1E-03 | Juvenile Arthritis | Intragenic | |
chr6 | 150,185,629 | RAET1E-AS1 |  − 27 | 5.1 | 8.9E-03 | Unknown | Intragenic | |
chr6 | 84,418,880 | SNAP91 |  − 8 | 1.5 | 9.8E-03 | Stroke | Intragenic | |
chr22 | 50,913,327 | SBF1 |  − 15 | 3.0 | 9.8E-03 | Charcot-Marie-Tooth disease | Intragenic | |
chr3 | 14,988,785 | FGD5-AS1 |  − 41 | 8.1 | 9.8E-03 | Systolic Blood Pressure | Intragenic | |
chr1 | 228,871,178 | RHOU |  − 6 | 1.2 | 9.8E-03 | Neoplasms | Intragenic | |
chr22 | 17,639,892 | HDHD5 |  − 8 | 1.7 | 9.8E-03 | Body Height | Intragenic | |